[From the bench to the clinic: The challenge of translating platelet production in vitro].

G Bouet, S Mookerjee, H Foster, A Waller, C Ghevaert
Author Information
  1. G Bouet: Mines Saint-Étienne, université Lyon, université Jean-Monnet, Inserm, U 1059 Sainbiose, Centre CIS, Saint-Étienne, France.
  2. S Mookerjee: Wellcome trust-medical research council Cambridge Stem Cell Institute and department of haematology, university of Cambridge, CB2 0PT Cambridge, UK.
  3. H Foster: Wellcome trust-medical research council Cambridge Stem Cell Institute and department of haematology, university of Cambridge, CB2 0PT Cambridge, UK.
  4. A Waller: Wellcome trust-medical research council Cambridge Stem Cell Institute and department of haematology, university of Cambridge, CB2 0PT Cambridge, UK.
  5. C Ghevaert: Wellcome trust-medical research council Cambridge Stem Cell Institute and department of haematology, university of Cambridge, CB2 0PT Cambridge, UK.

Abstract

Platelet transfusions, which are currently totally dependent on altruistic donations, are absolutely necessary to the treatment of patients with thrombocytopenia following trauma, surgery or other pathologies (especially malignancies). Producing platelets in vitro represent a major technological and scientific breathrough that would address logistical issues (supply chain, stock holding…) and medical concerns (compatibility and biosafety). The translation of this innovation will need to be accompanied by rigorous quality control, harmonised between laboratory when it comes to functionality and biosafety for use in the clinic.

Keywords

References

  1. Nature. 2017 May 11;545(7653):229-233 [PMID: 28445466]
  2. Acta Neuropathol Commun. 2019 May 29;7(1):95 [PMID: 31142360]
  3. Tissue Eng Part C Methods. 2011 Dec;17(12):1223-32 [PMID: 21895494]
  4. Protein Cell. 2014;5(8):569-79 [PMID: 24899134]
  5. J Thromb Haemost. 2007 Jul;5 Suppl 1:305-9 [PMID: 17635741]
  6. Cell. 2018 Jul 26;174(3):636-648.e18 [PMID: 30017246]
  7. Biomaterials. 2018 Sep;178:122-133 [PMID: 29920404]
  8. Blood. 1990 Jan 1;75(1):128-38 [PMID: 2294986]
  9. Platelets. 2016 Sep;27(6):526-34 [PMID: 27135140]
  10. Blood Transfus. 2017 May;15(3):222-231 [PMID: 28518049]
  11. Anal Bioanal Chem. 2015 Apr;407(10):2803-9 [PMID: 25701419]
  12. Blood. 2014 Sep 18;124(12):1857-67 [PMID: 25606631]
  13. Blood. 2012 Aug 23;120(8):1713-6 [PMID: 22773384]
  14. Sci Rep. 2016 Feb 22;6:21700 [PMID: 26898346]
  15. Biomaterials. 2018 Nov;182:135-144 [PMID: 30118981]
  16. Regen Med. 2019 Mar;14(3):243-255 [PMID: 30938271]
  17. Nat Commun. 2016 Apr 07;7:11208 [PMID: 27052461]
  18. Nat Commun. 2018 May 15;9(1):1925 [PMID: 29765017]
  19. Am J Pathol. 2001 May;158(5):1613-22 [PMID: 11337359]
  20. Stem Cell Reports. 2016 Nov 8;7(5):998-1012 [PMID: 27829140]
  21. Vox Sang. 2005 Apr;88(3):153-63 [PMID: 15787725]
  22. Curr Opin Genet Dev. 2010 Feb;20(1):91-5 [PMID: 19962879]
  23. J Thromb Haemost. 2011 Nov;9(11):2322-4 [PMID: 22947397]
  24. Stem Cell Reports. 2019 Mar 5;12(3):557-571 [PMID: 30773485]
  25. Biophys J. 2016 Aug 9;111(3):601-608 [PMID: 27508443]
  26. Cell Stem Cell. 2014 Apr 3;14(4):535-48 [PMID: 24529595]

Grants

  1. MC_PC_12009/Medical Research Council
  2. MC_PC_17230/Medical Research Council

Word Cloud

Created with Highcharts 10.0.0vitrobiosafetycontrolPlatelettransfusionscurrentlytotallydependentaltruisticdonationsabsolutelynecessarytreatmentpatientsthrombocytopeniafollowingtraumasurgerypathologiesespeciallymalignanciesProducingplateletsrepresentmajortechnologicalscientificbreathroughaddresslogisticalissuessupplychainstockholding…medicalconcernscompatibilitytranslationinnovationwillneedaccompaniedrigorousqualityharmonisedlaboratorycomesfunctionalityuseclinic[Frombenchclinic:challengetranslatingplateletproductionvitro]BiosafetyPlateletsQualityTransfusion

Similar Articles

Cited By